BIOCRYST PHARMACEUTICALS INC (BCRX)
Health Care · NASDAQ
BioCryst is a rare disease-focused biotech company commercializing ORLADEYO for hereditary angioedema and expanding its pipeline through structure-guided drug design and strategic M&A.
What BIOCRYST PHARMACEUTICALS INC does
BioCryst Pharmaceuticals is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company has built a commercial infrastructure around ORLADEYO, an oral, once-daily therapy for HAE prevention, and is leveraging this platform to bring first-in-class or best-in-class oral small-molecule and injectable protein therapeutics targeting rare diseases to market through both internal discovery and strategic acquisitions.
Themes: ["Hereditary angioedema / rare diseases"]
Fundamentals
- Price$10.72 as of 2026-07-09 close
- Market cap$2.8B as of 2026-07-10
- 1-year return+18.3% as of 2026-07-09 close
- P/E10.55 as of 2026-07-10
- Net margin-51.7% as of 2026-07-10
- Gross margin+97.8% as of 2026-07-10
- ROE-328.8% as of 2026-07-10
- Debt / equity2.26 as of 2026-07-10
- Revenue growth (YoY)+75.9% as of 2026-07-10
- Revenue CAGR (3y)+22.8% SEC XBRL
- Beta0.57 as of 2026-07-10
Key risks (from latest filing)
["Manufacturing delays and supply chain issues, including the recently identified manufacturing issue affecting oral pellet ORLADEYO fulfillment, which could impact future revenue and operating results"]
Competitors & peers
- Kalvista Pharmaceuticals (KALV)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.